Device Labs News Today

Spine devicemakers took important steps forward in innovation in 2023, and many are gearing up for exciting plans in the months ahead.

INCLINE VILLAGE, Nev., Oct. 9, 2023 /PRNewswire/ -- Kleiner Device Labs today announced that it was recently awarded a U.S. patent for its new KG®2 Surge® flow-thru interbody system. This adds to the

Kleiner Device Labs earned a U.S. patent for its KG2 Surge flow-thru interbody system, the company said Oct. 9.

/PRNewswire/ -- Jeff Kleiner, M.D., was a featured speaker at the Seattle Science Foundations July 21 spine symposium: New and Emerging Techniques &...

/PRNewswire/ -- Kleiner Device Labs (KDL) today announced that it will host a meeting room at McKinsey & Companys Early Stage Investor Conference on the...

/PRNewswire/ -- Kleiner Device Labs (KDL) today announced that it will host a meeting room at McKinsey & Companys Early Stage Investor Conference on the...

/PRNewswire/ -- Equifund (https://equifund.com), a private market investment platform that delivers vetted, early-stage investment opportunities to the public,...

/PRNewswire/ -- Kleiner Device Labs today announced that its new KG2™ Surge™ flow-thru interbody system was recognized with the Bronze award in the 2022...

/PRNewswire/ -- Kleiner Device Labs today announced that its new KG2TM SurgeTM flow-thru interbody system has been selected as a finalist in the 2022 Medical...

The (Forgotten) Deal Altria Group bought a 45 percent stake in leading cannabinoid company Cronos Group for about $1.8 billion. Altria  also has a warrant that would allow it to increase its stake in Cronos to about 55 percent at a price of $19 per share. It allows Cronos the flexibility to take investments from other companies such as, for example, a big food company. “The proceeds from Altria’s investment will enable us to more quickly expand our global infrastructure and distribution f...